CORDIS
EU research results

CORDIS

English EN
PERSONALIZED ENGINE FOR CANCER INTEGRATIVE STUDY AND EVALUATION

PERSONALIZED ENGINE FOR CANCER INTEGRATIVE STUDY AND EVALUATION

Objective

Despite of their great promise, high-throughput technologies in cancer research have often failed to translate to major therapeutic advances in the clinic. One challenge has been tumour heterogeneity, where multiple competing subclones coexist within a single tumour. Genomic heterogeneity renders it difficult to identify all driving molecular alterations, and thus results in therapies that only target subsets of aggressive tumour cells. Another challenge lies in the integration of multiple types of molecular data into mathematical disease models that can make actionable clinical statements.

We aim to develop predictive computational technology that can exploit molecular and clinical data to improve our understanding of disease mechanisms and to inform clinicians about optimized strategies for therapeutic intervention. We propose to focus on prostate cancer, a leading cause of cancer death amongst men in Europe, but also prone to over-treatment. Our approach combines the exploitation of genomic, transcriptomic, proteomic, and clinical data in primary and metastatic tumours, prospective cohorts of well characterized prostate cancer patients, drug screenings in cell lines, and the use of the Watson technology, a last generation cognitive computer developed at IBM.

The translational objective of this study is to develop technology for identifying disease mechanisms and produce treatment recommendations for individual patients based on a therapeutic biomarker panel. The proposed software framework will be accessible through a graphical interface that will facilitate its dissemination and use by researchers, clinicians, and biomedical industries. The framework will provide intuitive tools to deposit, share, analyze, and visualize molecular and clinical data; as well as to infer prognosis, elucidate implicated mechanisms and recommend therapy accordingly. This software framework will serve as a proof of concept for future development by industrial partners in Europe.

Coordinator

TECHNIKON FORSCHUNGS- UND PLANUNGSGESELLSCHAFT MBH

Address

Burgplatz 3a
9500 Villach

Austria

Activity type

Other

EU Contribution

€ 358 125

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

IBM RESEARCH GMBH

Switzerland

TECHNISCHE UNIVERSITAT DARMSTADT

Germany

EU Contribution

€ 539 375

UNIVERSITAETSKLINIKUM AACHEN

Germany

EU Contribution

€ 620 937,50

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

UNIVERSITAT ZURICH

Switzerland

BAYLOR COLLEGE OF MEDICINE

United States

EU Contribution

€ 561 250

INSTITUT CURIE

France

EU Contribution

€ 535 625

ASTRIDBIO TECHNOLOGIES KFT

Hungary

EU Contribution

€ 475 000

Project information

Grant agreement ID: 668858

Status

Closed project

  • Start date

    1 January 2016

  • End date

    31 December 2018

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 5 695 712,50

  • EU contribution

    € 3 090 312,50

Coordinated by:

TECHNIKON FORSCHUNGS- UND PLANUNGSGESELLSCHAFT MBH

Austria